Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 1
1952 1
1953 1
1954 2
1955 1
1956 2
1962 2
1963 9
1964 5
1965 1
1966 2
1967 8
1968 10
1969 12
1970 12
1971 24
1972 17
1973 10
1974 9
1975 11
1976 15
1977 15
1978 17
1979 17
1980 13
1981 22
1982 14
1983 15
1984 18
1985 16
1986 18
1987 18
1988 18
1989 17
1990 12
1991 10
1992 11
1993 11
1994 13
1995 12
1996 9
1997 13
1998 18
1999 27
2000 39
2001 26
2002 24
2003 28
2004 21
2005 18
2006 19
2007 28
2008 37
2009 29
2010 32
2011 44
2012 35
2013 41
2014 39
2015 33
2016 35
2017 38
2018 41
2019 51
2020 49
2021 29
Text availability
Article attribute
Article type
Publication date

Search Results

1,172 results
Results by year
Filters applied: . Clear all
Page 1
[The Adverse Effects of Ephedra Herb and the Safety of Ephedrine Alkaloids-free Ephedra Herb Extract (EFE)].
Odaguchi H, Hyuga S, Sekine M, Nakamori S, Takemoto H, Huang X, Oshima N, Shimada N, Yang J, Amakura Y, Hyuga M, Uchiyama N, Kobayashi Y, Hakamatsuka T, Goda Y, Hanawa T. Odaguchi H, et al. Among authors: shimada n. Yakugaku Zasshi. 2019;139(11):1417-1425. doi: 10.1248/yakushi.19-00122. Yakugaku Zasshi. 2019. PMID: 31685738 Free article. Review. Japanese.
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.
Hiraoka A, Kumada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Yokohama K, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M. Hiraoka A, et al. Among authors: shimada n. Liver Cancer. 2020 Jan;9(1):73-83. doi: 10.1159/000503031. Epub 2019 Oct 18. Liver Cancer. 2020. PMID: 32071911 Free PMC article.
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: shimada n. Cancer Med. 2019 Jul;8(8):3719-3728. doi: 10.1002/cam4.2241. Epub 2019 May 24. Cancer Med. 2019. PMID: 31127698 Free PMC article.
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.
Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: shimada n. Cancer Med. 2019 Jan;8(1):137-146. doi: 10.1002/cam4.1909. Epub 2018 Dec 21. Cancer Med. 2019. PMID: 30575325 Free PMC article.
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: shimada n. Oncology. 2019;97(5):277-285. doi: 10.1159/000501281. Epub 2019 Jul 15. Oncology. 2019. PMID: 31307035
IRF-7 is the master regulator of type-I interferon-dependent immune responses.
Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. Honda K, et al. Among authors: shimada n. Nature. 2005 Apr 7;434(7034):772-7. doi: 10.1038/nature03464. Epub 2005 Mar 30. Nature. 2005. PMID: 15800576 Free article.
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, Joko K, Shimada N, Deguchi A, Ishikawa T, Imai M, Tsuji K, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Hiraoka A, et al. Among authors: shimada n. Dig Dis. 2017;35(6):602-610. doi: 10.1159/000480256. Epub 2017 Oct 17. Dig Dis. 2017. PMID: 29040999 Clinical Trial.
1,172 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page